Sofinnova Partners, a prominent European venture capital firm focused on life sciences, has raised €1.2 billion over the past year. This includes more than €1 billion raised in the last quarter alone.
With this funding, the firm’s assets under management (AUM) have surpassed €4 billion. This growth reinforces its status as a key player in healthcare and sustainability innovation.
Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, stated that all seven of the firm’s investment strategies now have capital to support new life sciences companies. He anticipates funding 50 to 60 new companies aimed at addressing critical health and sustainability challenges.
Sofinnova’s latest funds have received backing from a diverse range of investors, including institutional investors, sovereign wealth funds, corporations, and family offices. This support highlights strong confidence in Sofinnova’s ability to identify high-potential opportunities.
As Sofinnova enhances its investment strategy, it is also adopting advanced technologies to improve decision-making. Recently, the firm launched an AI-powered platform called Sofinnova.ai, developed over the past five years.
This platform will transform how Sofinnova sources, analyzes, and supports innovative science and entrepreneurs. By leveraging advanced data analytics and machine learning, the firm aims to boost its capacity to discover disruptive innovations in life sciences.
